286
Participants
Start Date
September 30, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
March 31, 2015
Ritonavir boosted Atazanavir + Lamivudine
ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
Ritonavir boosted Atazanavir + 2 NRTIs
ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
Hospital de Elche, Elche
Hospital Marina Baixa, Villajoyosa
H. Germans Trias i Pujol, Badalona
Hospital General de Granollers, Granollers
Hospital de Jerez, Jerez de la Frontera
H. Juan Ramón Jiménez, Huelva
Complexo Hospitalario Universitario de Santiago, Santiago de Compostela
H. San Pedro, Logroño
Hospital Príncipe de Asturias, Alcalá de Henares
Hospital Severo Ochoa, Leganés
H. Clinico San Carlos, Madrid
H. Universitario Infanta Leonor, Madrid
H. Universitario Son Espases, Mallorca
Hospital Costa del Sol, Marbella
Hospital Arquitecto Marcide, Ferrol
Hospital Xeral Cíes, Vigo
H. Universitario Central de Asturias, Asturias
Hospital de Basurto, Basurto
Hospital Juan Canalejo, A Coruña
Hospital General de Alicante, Alicante
Hospital Santa Creu i Sant Pau, Barcelona
Hospital Vall d'Hebrón, Barcelona
Hospital Reina Sofía, Córdoba
Hospital Clínico San Cecilio, Granada
Hospital Virgen de las Nieves, Granada
Hospital Doce de Octubre, Madrid
Hospital Gregorio Marañón, Madrid
Hospital La Paz, Madrid
Hospital Ramón y Cajal, Madrid
Hospital de Mataró, Mataró
Hospital Virgen de la Victoria, Málaga
Hospital de Navarra, Pamplona
Hospital Donostia, San Sebastián
Hospital Marqués de Valdecilla, Santander
Hospital de Santa Tecla, Tarragona
Hospital La Fe, Valencia
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Fundacion SEIMC-GESIDA
OTHER